ROIV Stock Recent News

The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry's research and development. Large biotech companies such as Johnson and Johnson (NYSE: JNJ ), Merck (NYSE: MRK ), and AbbVie (NYSE: ABBV ) offer investors steady and continual growth as well as decent dividends.

Shares of Roivant ROIV rose almost 12% on Thursday after a Wall Street Journal (WSJ) article reported that Roche RHHBY was close to buying ROIV's inflammatory bowel disease (IBD) candidate, RVT-3101, for more than $7 billion.

Roivant Sciences is in talks to sell an experimental drug that can treat debilitating stomach diseases in a deal that could be valued at more than $7 billion.

Acadia Pharmaceuticals Inc.'s stock ACAD, -0.23% surged 18% in premarket trading after the company expanded drug rights to a treatment for a rare neurological disorder.

Shares of Roivant Sciences Ltd. ROIV, +1.58% surged in the extended session Thursday following a report that Roche Holding ROG, +0.62% was close to buying an experimental drug from the biotech company.

Roivant Sciences Ltd is attracting interest from large pharmaceutical companies for its inflammatory bowel disease drug, Bloomberg News reported on Thursday, citing people familiar with the matter.

Roivant Sciences Ltd. (ROIV) witnessed a jump in share price last session on above-average trading volume.

Roivant saw improved revenue and EPS in the fourth quarter. The company's lead therapy is plaque psoriasis cream Vtama.

After surviving some turbulent market conditions in its first years as a public company, Roivant Sciences Ltd. ROIV, +10.77% is taking on industry behemoths as it develops new treatments for ulcerative colitis, Crohn's disease and other conditions.

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.41.